All In Biotech

Drug Trial Radar · NCT02886715

A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris

A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both Active Treatments to a Vehicle Control in the Treatment of Acne Vulgaris

Last checked: Nov 19, 2026Latest source record: Aug 17, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,110 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,110

Actual

Start

Sep 21, 2016

Primary completion

May 31, 2017

Study completion May 31, 2017

Sponsor

Lead sponsor
Fougera Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Sep 1, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 12 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both Active Treatments to a Vehicle Control in the Treatment of Acne Vulgaris

Conditions

  • Acne Vulgaris

Interventions

  • Tazarotene Cream 0.1%Drug

    Tazarotene Cream 0.1% applied to cover the affected areas of the face once daily for 84 +/- 4 days.

  • Tazorac®Drug

    Tazorac® applied to cover the affected areas of the face once daily for 84 +/- 4 days.

  • PlaceboDrug

    Placebo (vehicle of the test product) applied to cover the affected areas of the face once daily for 84 +/- 4 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Inflammatory Lesion CountsTime frame: Week 12
  2. Change in Non-inflammatory Lesion CountsTime frame: Week 12

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • Fougera Investigational Site

    Tucson, Arizona

  • Fougera Investigational Site

    Conway, Arkansas

  • Fougera Investigational Site

    Hot Springs, Arkansas

  • Fougera Investigational Site

    Anaheim, California

  • Fougera Investigational Site

    La Mesa, California

  • Fougera Investigational Site

    Long Beach, California

  • Fougera Investigational Site

    Long Beach, California

  • Fougera Investigational Site

    Los Angeles, California

  • Fougera Investigational Site

    North Hollywood, California

  • Fougera Investigational Site

    San Diego, California

  • Fougera Investigational Site

    San Ramon, California

  • Fougera Investigational Site

    Upland, California

  • Fougera Investigational Site

    West Covina, California

  • Fougera Investigational Site

    Coral Gables, Florida

  • Fougera Investigational Site

    Miami, Florida

  • Fougera Investigational Site

    Miami, Florida

  • Fougera Investigational Site

    Miami Gardens, Florida

  • Fougera Investigational Site

    Miramar, Florida

  • Fougera Investigational Site

    Sweetwater, Florida

  • Fougera Investigational Site

    Plainfield, Indiana

  • Fougera Investigational Site

    High Point, North Carolina

  • Fougera Investigational Site

    Hazleton, Pennsylvania

  • Fougera Investigational Site

    Upper Saint Clair, Pennsylvania

  • Fougera Investigational Site

    Chattanooga, Tennessee

  • Fougera Investigational Site

    Austin, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.